Mundipharma and Prestige Enters into an Exclusive License and Supply Agreement for Tuznue (biosimilar, trastuzumab, HD201)

 Mundipharma and Prestige Enters into an Exclusive License and Supply Agreement for Tuznue (biosimilar, trastuzumab, HD201)

Egis Pharmaceuticals Signs an Exclusive Distribution Agreement with Mundipharma for Pelmeg (pegfilgrastim, biosimilar) in Central and Eastern Europe

Shots:

  • Mundipharma to get exclusive rights to distribute, market and commercialize Tuznue in selected EU countries following marketing authorization, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria
  • The EMA approval of Tuznue is based on positive results confirming it as a biosimilar to Herceptin in terms of clinical response and PK with a comparable safety profile to the range previously observed in other trastuzumab biosimilar trials
  • Tuznue is a mAb and a biosimilar to Roche’s Herceptin, that interferes with the human epidermal growth factor receptor 2 (HER2) targeted to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma

Click here to read full press release/ article | Ref: Mundipharma | Image: Twitter  

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post